HRP20211352T1 - Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa - Google Patents
Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa Download PDFInfo
- Publication number
- HRP20211352T1 HRP20211352T1 HRP20211352TT HRP20211352T HRP20211352T1 HR P20211352 T1 HRP20211352 T1 HR P20211352T1 HR P20211352T T HRP20211352T T HR P20211352TT HR P20211352 T HRP20211352 T HR P20211352T HR P20211352 T1 HRP20211352 T1 HR P20211352T1
- Authority
- HR
- Croatia
- Prior art keywords
- general formula
- compounds
- compound
- formula
- image
- Prior art date
Links
- 208000001490 Dengue Diseases 0.000 title claims 2
- 206010012310 Dengue fever Diseases 0.000 title claims 2
- 208000025729 dengue disease Diseases 0.000 title claims 2
- -1 di-substituted indole Chemical class 0.000 title claims 2
- 229940123627 Viral replication inhibitor Drugs 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 31
- 239000002904 solvent Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- XBZBDCOVNQRWPT-UHFFFAOYSA-N 3-methoxy-5-methylsulfonylaniline Chemical compound COC1=CC(N)=CC(S(C)(=O)=O)=C1 XBZBDCOVNQRWPT-UHFFFAOYSA-N 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 230000031709 bromination Effects 0.000 claims 3
- 238000005893 bromination reaction Methods 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 238000000926 separation method Methods 0.000 claims 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 2
- LXVQXKPZQAVYDR-UHFFFAOYSA-N 4-chloro-2-(2-phenylmethoxyethoxy)benzaldehyde Chemical compound C(C1=CC=CC=C1)OCCOC1=C(C=O)C=CC(=C1)Cl LXVQXKPZQAVYDR-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 150000002466 imines Chemical class 0.000 claims 2
- 150000002475 indoles Chemical class 0.000 claims 2
- 239000000543 intermediate Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- PWDKXDCJQQRBHM-UHFFFAOYSA-N 2-[4-chloro-2-(2-hydroxyethoxy)phenyl]acetic acid Chemical compound ClC1=CC(=C(C=C1)CC(=O)O)OCCO PWDKXDCJQQRBHM-UHFFFAOYSA-N 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 claims 1
- 239000002841 Lewis acid Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000012320 chlorinating reagent Substances 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000013067 intermediate product Substances 0.000 claims 1
- 150000007517 lewis acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000005057 refrigeration Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 238000006891 umpolung reaction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Spoj s formulom (I)
[image]
njegov stereo-izomerni oblik, njegova farmaceutski prihvatljiva sol, solvat ili polimorf ; navedeni spoj je odabran iz skupine pri čemu:
R1 je H, R2 je F, Cl ili OCH3 i R3 je H;
R1 je H, R2 je F ili Cl i R3 je CH3;
R1 je CH3, R2 je OCH3 i R3 je H;
R1 je F, R2 je F i R3 je H;
R1 je CH3, R2 je F i R3 je H;
R1 je CF3 ili OCF3 i R2 je H i R3 je H;
R1 je OCF3, R2 je OCH3 i R3 je H ili
R1 je OCF3 , R2 je H i R3 je CH3.
2. Spoj ili njegov stereo-izomerni oblik, njegova farmaceutski prihvatljiva sol, solvat ili polimorf prema patentnom zahtjevu 1 naznačen time što je navedeni spoj odabran iz skupine:
[image]
[image]
[image]
[image]
3. Farmaceutski pripravak naznačen time što sadrži spoj s formulom (I) ili stereoizomerni oblik, njegovu farmaceutski prihvatljivu sol, solvat ili polimorf prema patentnom zahtjevu 1 ili 2 zajedno s jednim ili više farmaceutski prihvatljivih pomoćnih sastojaka, razrjeđivača ili nosača.
4. Spoj s formulom (I) ili stereoizomerni oblik, njegova farmaceutski prihvatljiva sol, solvat ili polimorf prema patentnom zahtjevu 1 ili farmaceutski pripravak prema patentnom zahtjevu 3 za upotrebu kao lijek.
5. Spoj s formulom (I) ili stereoizomerni oblik, njegova farmaceutski prihvatljiva sol, solvat ili polimorf prema patentnom zahtjevu 1 ili farmaceutski pripravak prema patentnom zahtjevu 3 za upotrebu za liječenje denga groznice.
6. Spoj predstavljen sljedećom strukturnom formulom (I)
[image]
njegov stereo-izomerni oblik, njegova farmaceutski prihvatljiva sol, solvat ili polimorf ; navedeni spoj je odabran iz skupine pri čemu:
R1 je H, R2 je F, Cl ili OCH3 i R3 je H;
R1 je H, R2 je F ili Cl i R3 je CH3;
R1 je CH3, R2 je OCH3 i R3 je H;
R1 je F, R2 je F i R3 je H;
R1 je CH3, R2 je F i R3 je H;
R1 je CF3 ili OCF3 i R2 je H i R3 je H;
R1 je OCF3, R2 je OCH3 i R3 je H ili
R1 je OCF3 , R2 je H i R3 je CH3
za uporabu u inhibiranju replikacije denga virusa u biološkom uzorku ili pacijentu.
7. Spoj za uporabu spoja prema patentnom zahtjevu 6 naznačen time što dalje obuhvaća istodobnu primjenu dodatnog terapijskog sredstva.
8. Spoj za uporabu prema patentnom zahtjevu 7 naznačen time što je navedeno dodatno terapijsko sredstvo još jedno antivirusno sredstvo.
9. Postupak sinteze spojeva formule (I) prema zahtjevu 1 ili 2 naznačen time što obuhvaća korake:
a) pretvaranje 2-(4-klor-2-(2-hidroksietoksi)fenil)octene kiseline s općom formulom (II) u derivat kiselog klorida s općom formulom (III) s klorirajućim reagensom, pri čemu je PG zaštitna skupina;
b) Friedel-Craftsovu reakciju kiselog klorida s općom formulom (III) sa supstituiranim indolom s općom formulom (IV) izvedenu uporabom reagensa Lewisove kiseline u prikladnom otapalu i pod prikladnim reakcijskim uvjetima koji obično uključuju hlađenje, da se dobije 3-acilirani indol s općom formulom (V), pri čemu R1, R2 i R3 imaju isto značenje kao u zahtjevu 1;
c) uklanjanje zaštitne skupine PG iz spojeva s općom formulom (V) da se dobiju spojevi s općom formulom (VI);
d) bromiranje (VI) s reagensom u prikladnom otapalu da se dobiju spojevi s općom formulom (VII);
e) reakciju spojeva s općom formulom (VII) s 3-metoksi-5-(metil-sulfonil)anilinom (VIII) u prikladnom otapalu i po izboru upotrebom baze da se dobiju spojevi s općom formulom I kao racemične smjese;
f) kiralno razdvajanje spojeva s općom formulom I radi dobivanja enantiomera A i B s općom formulom I
[image]
10. Postupak prema patentnom zahtjevu 9, naznačen time što se međuprodukti s općom formulom (V) pretvaraju u spojeve s općom formulom I slijedeći korake:
i) bromiranje na alfa položaju karbonilne funkcije međuprodukata s općom formulom (V) s prikladnim reagensom za bromiranje u prikladnom otapalu da se dobiju spojevi s općom formulom (IX), pri čemu PG je kako je definirano u zahtjevu 10 i R1, R2 i R3 imaju isto značenje kao u zahtjevu 1;
ii) reakciju spojeva s općom formulom (IX) s 3-metoksi-5-(metilsulfonil)anilinom (VIII) u prikladnom otapalu i po izboru korištenje baze da se dobiju spojevi s općom formulom (X);
iii) uklanjanje O-zaštitne skupine iz spojeva s općom formulom (X) u prikladnom otapalu radi dobivanja spojeva s općom formulom I kao racemičnih smjesa;
iv) kiralno razdvajanje spojeva s općom formulom I radi dobivanja enantiomera A i B s općom formulom I
[image]
11. Postupak sinteze spojeva formule (I) prema zahtjevu 1 ili 2 naznačen time što obuhvaća korake:
I) kondenzaciju 2-(2-(benziloksi)-etoksi)-4-klorobenzaldehida (XI) s 3-metoksi-5-(metilsulfonil)anilinom (VIII) ) u prikladnom otapalu da se dobije međuprodukt imin (XII);
II) dodavanje supstituiranog N-Boc-zaštićenog indol-karboksaldehida s općom formulom (XIII), u prisutnosti Umpolung katalizatora daje spojeve s općom formulom (X);
III) uklanjanje O-zaštitne skupine (PG) iz spojeva s općom formulom (X) u prikladnom otapalu radi dobivanja spojeva s općom formulom I kao racemičnih smjesa;
IV) kiralno razdvajanje spojeva s općom formulom I radi dobivanja enantiomera A i B s općom formulom I
[image]
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15185523 | 2015-09-16 | ||
| EP16163472 | 2016-04-01 | ||
| PCT/EP2016/071845 WO2017046255A1 (en) | 2015-09-16 | 2016-09-15 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| EP16766010.9A EP3350162B1 (en) | 2015-09-16 | 2016-09-15 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211352T1 true HRP20211352T1 (hr) | 2022-02-04 |
Family
ID=56926217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211352TT HRP20211352T1 (hr) | 2015-09-16 | 2016-09-15 | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10765662B2 (hr) |
| EP (1) | EP3350162B1 (hr) |
| JP (2) | JP7050666B2 (hr) |
| KR (1) | KR102646174B1 (hr) |
| CN (1) | CN108473422B (hr) |
| AU (1) | AU2016324982B2 (hr) |
| CA (1) | CA2996979C (hr) |
| CL (1) | CL2018000696A1 (hr) |
| CO (1) | CO2018003471A2 (hr) |
| CR (1) | CR20180213A (hr) |
| DK (1) | DK3350162T3 (hr) |
| EA (1) | EA035663B1 (hr) |
| EC (1) | ECSP18020055A (hr) |
| ES (1) | ES2893298T3 (hr) |
| HK (1) | HK1257842A1 (hr) |
| HR (1) | HRP20211352T1 (hr) |
| HU (1) | HUE055870T2 (hr) |
| IL (1) | IL258043B (hr) |
| JO (1) | JOP20160198B1 (hr) |
| LT (1) | LT3350162T (hr) |
| MA (1) | MA42810A (hr) |
| MX (1) | MX2018003255A (hr) |
| NI (1) | NI201800039A (hr) |
| PE (1) | PE20181165A1 (hr) |
| PH (1) | PH12018500576A1 (hr) |
| SI (1) | SI3350162T1 (hr) |
| TW (1) | TWI758255B (hr) |
| UA (1) | UA122973C2 (hr) |
| UY (1) | UY36903A (hr) |
| WO (1) | WO2017046255A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) * | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| PE20220502A1 (es) | 2015-12-16 | 2022-04-07 | Loxo Oncology Inc | Compuestos utiles como inhibidores de cinasa |
| SI3436435T1 (sl) | 2016-03-31 | 2021-08-31 | Janssen Pharmaceuticals, Inc. | Substituirani derivati indolina kot zaviralci replikacije virusa denga |
| SG11201808270PA (en) | 2016-03-31 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JP7007290B2 (ja) * | 2016-04-01 | 2022-01-24 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | デングウイルス複製阻害剤としての置換インドール化合物誘導体 |
| JOP20180026A1 (ar) * | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| AU2018274100B2 (en) | 2017-05-22 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| IL270727B2 (en) | 2017-05-22 | 2023-03-01 | Janssen Pharmaceuticals Inc | Transduced indulin derivatives as inhibitors of dengue virus replication |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999021559A1 (en) | 1997-10-27 | 1999-05-06 | Eli Lilly And Company | MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS |
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| JP2005520795A (ja) | 2001-12-12 | 2005-07-14 | コンフォーマ・セラピューティクス・コーポレイション | Ｈｓｐ９０阻害活性を有するプリン類似体 |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| CN101103026A (zh) | 2005-01-14 | 2008-01-09 | 健亚生物科技公司 | 用于治疗病毒感染的吲哚衍生物 |
| CA2597213A1 (en) | 2005-02-09 | 2006-09-14 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
| CA2682483A1 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
| FR2928645A1 (fr) * | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| BRPI0909985A2 (pt) | 2008-06-03 | 2015-08-25 | Siga Technologies Inc | Composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada à mesma |
| CN102186833A (zh) * | 2008-08-18 | 2011-09-14 | 耶鲁大学 | Mif调节剂 |
| US8143259B2 (en) | 2008-08-19 | 2012-03-27 | Janssen Pharmaceutica, Nv | Cold menthol receptor antagonists |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| PT2523951E (pt) | 2010-01-15 | 2015-09-14 | Gilead Sciences Inc | Inibidores de vírus flaviviridae |
| US20130023532A1 (en) | 2010-03-26 | 2013-01-24 | Casillas Linda N | Indazolyl-pyrimidines as kinase inhibitors |
| GB201116559D0 (en) * | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| DK3060547T3 (en) | 2013-10-23 | 2018-01-15 | Janssen Sciences Ireland Uc | CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B |
| EP3988549A1 (en) | 2014-01-31 | 2022-04-27 | Bristol-Myers Squibb Company | Macrocycles with heterocyclic p2' groups as factor xia inhibitors |
| CA2958022A1 (en) * | 2014-10-01 | 2016-04-07 | Janssen Pharmaceuticals, Inc | Mono- or di-substituted indoles as dengue viral replication inhibitors |
| RS58461B1 (sr) | 2014-10-01 | 2019-04-30 | Janssen Pharmaceuticals Inc | Mono- ili di-supstituisani derivati indola kao inhibitori replikacije virusa denge |
| NO2721243T3 (hr) | 2014-10-01 | 2018-10-20 | ||
| JOP20150335B1 (ar) | 2015-01-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| PT3370698T (pt) | 2015-11-03 | 2022-03-02 | Zoetis Services Llc | Compósitos de polímero sol-gel e utilizações dos mesmos |
| CN109715613B (zh) | 2016-03-31 | 2021-07-30 | 武田药品工业株式会社 | 杂环化合物 |
| SG11201808270PA (en) | 2016-03-31 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| SI3436435T1 (sl) | 2016-03-31 | 2021-08-31 | Janssen Pharmaceuticals, Inc. | Substituirani derivati indolina kot zaviralci replikacije virusa denga |
| WO2017167832A1 (en) | 2016-04-01 | 2017-10-05 | Basf Se | Bicyclic compounds |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CA3018986A1 (en) | 2016-04-01 | 2017-10-05 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| MY201207A (en) | 2016-04-01 | 2024-02-09 | Amgen Inc | Chimeric receptors to flt3 and methods of use thereof |
| JP7007290B2 (ja) | 2016-04-01 | 2022-01-24 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | デングウイルス複製阻害剤としての置換インドール化合物誘導体 |
| CR20210084A (es) | 2016-04-01 | 2021-03-26 | Amgen Inc | Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480) |
| CN109328074A (zh) | 2016-04-01 | 2019-02-12 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| IL270727B2 (en) | 2017-05-22 | 2023-03-01 | Janssen Pharmaceuticals Inc | Transduced indulin derivatives as inhibitors of dengue virus replication |
| AU2018274100B2 (en) | 2017-05-22 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
-
2016
- 2016-09-06 JO JOP/2016/0198A patent/JOP20160198B1/ar active
- 2016-09-13 TW TW105129689A patent/TWI758255B/zh active
- 2016-09-15 UA UAA201804007A patent/UA122973C2/uk unknown
- 2016-09-15 LT LTEPPCT/EP2016/071845T patent/LT3350162T/lt unknown
- 2016-09-15 DK DK16766010.9T patent/DK3350162T3/da active
- 2016-09-15 EA EA201890722A patent/EA035663B1/ru not_active IP Right Cessation
- 2016-09-15 MA MA042810A patent/MA42810A/fr unknown
- 2016-09-15 CA CA2996979A patent/CA2996979C/en active Active
- 2016-09-15 MX MX2018003255A patent/MX2018003255A/es unknown
- 2016-09-15 CN CN201680053616.2A patent/CN108473422B/zh active Active
- 2016-09-15 PE PE2018000399A patent/PE20181165A1/es unknown
- 2016-09-15 US US15/759,846 patent/US10765662B2/en active Active
- 2016-09-15 HU HUE16766010A patent/HUE055870T2/hu unknown
- 2016-09-15 ES ES16766010T patent/ES2893298T3/es active Active
- 2016-09-15 SI SI201631355T patent/SI3350162T1/sl unknown
- 2016-09-15 AU AU2016324982A patent/AU2016324982B2/en active Active
- 2016-09-15 JP JP2018513474A patent/JP7050666B2/ja active Active
- 2016-09-15 EP EP16766010.9A patent/EP3350162B1/en active Active
- 2016-09-15 HR HRP20211352TT patent/HRP20211352T1/hr unknown
- 2016-09-15 KR KR1020187009763A patent/KR102646174B1/ko active IP Right Grant
- 2016-09-15 CR CR20180213A patent/CR20180213A/es unknown
- 2016-09-15 WO PCT/EP2016/071845 patent/WO2017046255A1/en active Application Filing
- 2016-09-16 UY UY0001036903A patent/UY36903A/es not_active Application Discontinuation
-
2018
- 2018-03-12 IL IL258043A patent/IL258043B/en unknown
- 2018-03-14 EC ECIEPI201820055A patent/ECSP18020055A/es unknown
- 2018-03-15 PH PH12018500576A patent/PH12018500576A1/en unknown
- 2018-03-15 CL CL2018000696A patent/CL2018000696A1/es unknown
- 2018-03-15 NI NI201800039A patent/NI201800039A/es unknown
- 2018-03-28 CO CONC2018/0003471A patent/CO2018003471A2/es unknown
-
2019
- 2019-01-07 HK HK19100198.9A patent/HK1257842A1/zh unknown
-
2021
- 2021-08-12 JP JP2021131751A patent/JP2021181485A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211352T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20211782T1 (hr) | Derivati indola kao inhibitori replikacije denga virusa | |
| HRP20210675T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20210847T1 (hr) | Supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20200408T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| JP2018515495A5 (hr) | ||
| JP2017531619A5 (hr) | ||
| ES2585396T3 (es) | Alquilamidas como inhibidores de la unión del VIH | |
| HRP20161478T1 (hr) | Inhibitori protein kinaze (varijante), njihova upotreba za liječenje neuroloških bolesti, kao i farmaceutski pripravak koji se na njima temelji | |
| JP2019510034A5 (hr) | ||
| WO2020016749A3 (en) | Chemical process for preparing phenylpiperidinyl indole derivatives | |
| BR112014020444A2 (pt) | Processo para a preparação de (s)-1-(3-etoxi-4-metoxifenil)-2-metanossulfoniletilamina ecomposto | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| CN106103445A (zh) | 作为cdk抑制剂的吡唑并[1,5‑a]嘧啶‑5,7‑二胺化合物和它们的治疗用途 | |
| JP2017504576A5 (hr) | ||
| CO6241112A2 (es) | Sales novedosas de piperazina como antagonistas d3/d2 | |
| RU2017136715A (ru) | Производное имидазоизоиндола, способ его получения и медицинское применение | |
| WO2020097400A8 (en) | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof | |
| WO2021076902A1 (en) | INHIBITING HUMAN INTEGRIN α 4 β 7 | |
| JP2018522867A5 (hr) | ||
| JP2020532545A5 (hr) | ||
| JP2016528273A5 (hr) | ||
| JP2016508145A5 (hr) | ||
| KR20200124710A (ko) | 이미다졸계 화합물의 결정 형태, 염 형태 및 그의 제조 방법 | |
| WO2018174442A1 (ko) | 코로나 바이러스 감염으로 인한 질환 치료용 화합물 |